Last reviewed · How we verify
NCT07132801
Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
NA trial testing Qualia NAD⁺ version 1 in NAD in 180 participants. Not yet recruiting.
30 November 2025
Quick facts
| Lead sponsor | Qualia Life Sciences |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 180 |
| Start date | 13 October 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 15 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Qualia NAD⁺ version 1
- Qualia NAD⁺ version 2
- Placebo
Conditions studied
- NAD — all drugs for NAD →
- NAD+ Levels in the Blood — all drugs for NAD+ Levels in the Blood →
Sponsor
Qualia Life Sciences
Who can join
Adults 35 to 75, any sex, with NAD or NAD+ Levels in the Blood. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07132801
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NAD
Currently open trials in the same condition.
- NCT07203131 — Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Ca · NA · recruiting
- NCT06005350 — Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+) · NA · active not recruiting
Other Qualia Life Sciences trials
Trials by the same sponsor.
- NCT07361757 — Qualia Perimenopause Efficacy and Tolerability Study: An Open-label 3-Arm Trial · NA · not yet recruiting
- NCT07285109 — The Impact of Qualia Vitamin C+ on Blood Vitamin C Levels · NA · recruiting
- NCT07221955 — The Impact of Qualia Gluthathione+ on Blood Glutathione Levels · NA · not yet recruiting
- NCT07156526 — Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life · NA · not yet recruiting
- NCT07028255 — Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07132801 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qualia Life Sciences
- Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07132801.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing